hzVSF-v13 + tenofovir

hzVSF-v13 + tenofovir is a combination therapy being investigated for chronic hepatitis B and other viral infections. hzVSF-v13 is a monoclonal IgG4 antibody targeting vimentin expressed on the surface of virus-infected cells, which confers both antiviral and anti-inflammatory activity. Tenofovir is a nucleotide analog reverse transcriptase inhibitor that blocks viral DNA replication and is a mainstay in hepatitis B and HIV therapy. Preclinical and early-phase clinical studies have shown that co-administering hzVSF-v13 with tenofovir produces a more profound suppression of viral markers than either drug alone, likely via complementary mechanisms: hzVSF-v13 inhibits virus cell entry and modulates immune cells, while tenofovir directly inhibits viral polymerases[1][4][7].

Other names

hzVSFtenofovirtenofovir disoproxil fumarate